Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11609MR)

This product GTTS-WQ11609MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Mus musculus; Humanized
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11609MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3617MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ9257MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ1194MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ5967MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ432MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 3C23K
GTTS-WQ12834MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ11459MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ11284MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI4893
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW